Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201703-14 Determination of biological mechanisms and efficacy evaluation of novel vaccine lead (△SpA-Insoluble Cell Wall, named ICW) for methicillin-resistant Staphylococcus aureus (MRSA) infection in animal infection models(Infectious Diseases, Protein) [08.27.2018]

PRINT

Development and Market Objectives

- Until now, there is no vaccine for methicillin-resistant S. aureus infection.

- The object of this proposal is to address the mode of action and efficacy of memory immune responses of our lead compound (S. aureus particulate cell wall (PCW) (named as lead compounds).

- In vivo protection efficacies of lead compounds will be examined in the three MRSA infection animal models, such as mice, rabbits and guinea pigs

- Finally, we target to find the best lead compound capable to be licensed out to global companies.

Unmet Medical Need & Target Patients

A. Target Patients

Patient group caused by MRSA infection

 1) Patients with diabetes, end stage renal failure, and patients taking immunosuppressant or anticancer drug.

 2) Patients with artificial joints, artificial teeth, artificial valves, osteomyelitic patients, low birth weight infants, patients inserted a catheter, patients with endobronchial tubes, surgical subjects.

 3) Patients with folliculitis, cellulitis, skin-necrosis, endocarditis, osteomyelitis, sepsis.

 

B. Unmet Medical Needs

- Diseases that are clinically problematic due to MRSA infection are resistant to current available multiple antibiotics which are useful in clinical use. So, the healing effect decreases, and it is suffering greatly from efficient treatments.

- Until recently, several foreign researchers have attempted several clinical trials to develop a vaccine for preventive or therapeutic for interventions that could replace antibiotics. However, there is still no effective MRSA vaccines.

- Based on these clinical trial results, the MRSA vaccine can be presented as shown below.

  a. A new vaccine should simultaneously induce host cellular immune response and humoral immune response.

 b. A new vaccine should control the damage of the host immune response by the virulence factor of MRSA.

- It should produce novel functional effective antibodies different from the existing antibody formed.

Status

1. Screening of S. aureus particulate cell walls (PCWs)

 - Separation of S. aureus cell walls components (PCWs) from several S. aureus mutant strains.

 - identification of biochemical characterization of these purified PCWs.

 - Study of interaction between defense system and PCWs.

 

2. Deduction of lead compounds

 - Screening lead compounds after exploring the innate immune and acquired responses

 - Derive leading substances to control MRSA infection in skin infections, abdominal and subcutaneous models

 

3. Investigation of mode of action

  - Identification of the MOA of leading substances is now on-going

Intellectual Property

- 2 Patents in December, 2017.

  10-2017-0164298(Dec. 1. 2017)

  10-2017-0164299(Dec. 1. 2017)

 

- Plan to patent application for this experimental result and final lead substances.

Competitive Advantages

- Vaccine candidate substances from foreign competitors have bacterial clearance mechanism by antibody-mediated opsonophagocytosis. But, our lead compound differentiates itself from competitors because it has the activation mechanism both a phagocyte-mediated cellular immunity and an antibody-mediated humoral immunity.

 

- if their effects against MRSA infection can be demonstrated, it is expected to receive external attention as a first-in-class vaccine against MRSA.

Indication

MRSA

Research Period

2017.10.1-2018.11.30

Company

Pusan National University

Developmental Stage

Generation

Additional Information

Contact Information

Contact
Address Company Name: Pusan National University
WebSite Homepage: http://protein.pusan.ac.kr Contact Person: Professor Lee Bok Luel
E-mail: brlee@pusan.ac.kr Contact: +82-51-510-2809

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code